Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Advanced Unresectable or Metastatic Breast Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT00559507
What this trial is testing

Saracatinib in Treating Patients With Metastatic or Locally Advanced Breast Cancer That Cannot Be Removed By Surgery

Who this might be right for
Estrogen Receptor-negative Breast CancerMale Breast CancerProgesterone Receptor-negative Breast Cancer+4 more
National Cancer Institute (NCI) 12
Early research (Phase 1)Study completedNCT02898207
What this trial is testing

Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer

Who this might be right for
Metastatic High Grade Fallopian Tube Serous AdenocarcinomaMetastatic Malignant Solid NeoplasmMetastatic Primary Peritoneal Serous Adenocarcinoma+16 more
National Cancer Institute (NCI) 28
Testing effectiveness (Phase 2)Study completedNCT02614794
What this trial is testing

Tucatinib vs. Placebo in Combination With Capecitabine & Trastuzumab in Patients With Advanced HER2+ Breast Cancer

Who this might be right for
HER2 Positive Breast Cancer
Seagen Inc. 612
Testing effectiveness (Phase 2)Active Not RecruitingNCT06172127
What this trial is testing

PHESGO Maintenance After T-DXd Short Induction for HER2+ Unresectable Locally Recurrent or Metastatic Breast Cancer

Who this might be right for
HER2-positive Breast Cancer
MedSIR 165
Early research (Phase 1)Study completedNCT02776917
What this trial is testing

Study of Cirmtuzumab and Paclitaxel for Metastatic or Locally Advanced, Unresectable Breast Cancer

Who this might be right for
Breast Neoplasms
Barbara Parker, MD 23
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07824869
What this trial is testing

A Phase II Study of HLX22 in Combination With Trastuzumab and Chemotherapy in HER2-Positive Locally Advanced or Metastatic Breast Cancer Patients

Who this might be right for
HER2 + Breast Cancer
Shanghai Henlius Biotech 90
Early research (Phase 1)Looking for participantsNCT06440005
What this trial is testing

Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors

Who this might be right for
CancerAdvanced CancerLocally Advanced Carcinoma+8 more
Angiex, Inc. 80
Testing effectiveness (Phase 2)Ended earlyNCT01912963
What this trial is testing

Phase II Study of Eribulin Mesylate, Trastuzumab, and Pertuzumab in Women With Metastatic, Unresectable Locally Advanced, or Locally Recurrent HER2-Positive Breast Cancer

Who this might be right for
HER2-positive Breast CancerMetastatic Breast Cancer
Dana-Farber Cancer Institute 32
Not applicableActive Not RecruitingNCT07018427
What this trial is testing

Real-world Study of Sacituzumab Govitecan Monotherapy or Combination Therapy in Recurrent or Metastatic HER2-negative Breast Cancer

Who this might be right for
Breast NeoplasmsTriple Negative Breast CancerHR+, HER2-, Advanced Breast Cancer+1 more
Peking University Cancer Hospital & Institute 70
Not applicableStudy completedNCT02913456
What this trial is testing

A European Registry Study to Prospectively Observe Treatment Patterns and Outcomes in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Unresectable Locally Advanced (LA) or Metastatic Breast Cancer (mBC) (SAMANTHA)

Who this might be right for
Breast Cancer
Hoffmann-La Roche 629
Testing effectiveness (Phase 2)Looking for participantsNCT05706129
What this trial is testing

Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors

Who this might be right for
Clear Cell Renal Cell Cancer (ccRCC)Pancreatic Ductal Adenocarcinoma (PDAC)Colorectal Cancer (CRC)+6 more
Lumara Bio Oncologics GmbH 270
Early research (Phase 1)Study completedNCT00028496
What this trial is testing

Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer

Who this might be right for
Adenocarcinoma of the ColonAdenocarcinoma of the GallbladderAdenocarcinoma of the Pancreas+39 more
National Cancer Institute (NCI) 48
Testing effectiveness (Phase 2)Active Not RecruitingNCT05458674
What this trial is testing

Tucatinib+Trastuzumab+Eribulin in HER2+ MBC

Who this might be right for
Breast CancerPretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Cancer
Criterium, Inc. 17
Early research (Phase 1)Looking for participantsNCT05098210
What this trial is testing

Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer

Who this might be right for
Anatomic Stage IV Breast Cancer AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8Locally Advanced Cutaneous Melanoma+22 more
Fred Hutchinson Cancer Center 28
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06775236
What this trial is testing

Clinical Trial of SYS6010±SYH2051 Versus Chemotherapy in Advanced Breast Cancer and Other Solid Tumors

Who this might be right for
Advanced Solid TumorsBreast Cancer
CSPC Megalith Biopharmaceutical Co.,Ltd. 410
Not applicableApproved For MarketingNCT04220203
What this trial is testing

Treatment Protocol of Tucatinib With Capecitabine and Trastuzumab in Patients With Unresectable Previously Treated HER2+ Breast Cancer

Who this might be right for
HER2-positive Breast Cancer
Seagen, a wholly owned subsidiary of Pfizer
Not applicableEnded earlyNCT00896467
What this trial is testing

Psychological and Emotional Impact in Patients Undergoing Treatment For Metastatic Cancer Either in a Clinical Trial or as Standard Off-Trial Therapy

Who this might be right for
Anal CancerAnxiety DisorderBreast Cancer+9 more
Centre Oscar Lambret 200
Testing effectiveness (Phase 2)Active Not RecruitingNCT04639219
What this trial is testing

T-DXd for the Treatment of Solid Tumors Harboring HER2 Activating Mutations

Who this might be right for
Advanced Solid Tumors With HER2 Mutation,eg:Colorectal,Urothelial,Gastric, Hepatobiliary,Endometrial,Melanoma,Ovarian,Cervical,Salivary Gland,Pancreatic,Breast
AstraZeneca 102
Early research (Phase 1)Looking for participantsNCT06493864
What this trial is testing

BL-B16D1 in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors

Who this might be right for
Breast CancerSolid Tumor
Sichuan Baili Pharmaceutical Co., Ltd. 21
Large-scale testing (Phase 3)Looking for participantsNCT06767527
What this trial is testing

AK112 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/ Metastatic Triple-negative Breast Cancer

Who this might be right for
Triple-Negative Breast Cancer (TNBC)
Akeso 416
Next Page